Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd Corporation (OTC PINK:HALB) announced a breakthrough achievement in neuroscience by successfully eradicating Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) during preliminary testing. This advancement is critical, as IL-1 is linked to various severe diseases including Alzheimer's and Multiple Sclerosis. The company's patented technology has previously eliminated other inflammatory cytokines, enhancing prospects for treating neurodegenerative conditions. Halberd aims to revolutionize treatments for diseases such as Alzheimer’s and Parkinson’s through ongoing research and patent protections.
Halberd Corporation (OTC PINK:HALB) has announced successful verification tests demonstrating a 100% elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). This breakthrough, achieved through their patented process and laser irradiation, indicates potential new treatments for conditions like Alzheimer's Disease and PTSD. The company also highlighted previous success in eliminating Phosphorylated Tau and Interleukin 6, emphasizing ongoing research to address other inflammatory markers associated with neurodegenerative diseases.
Halberd Corporation (OTC PINK:HALB) announced a significant breakthrough in treating Alzheimer's Disease by eradicating 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) using its patented process and laser technology. This inflammatory cytokine is linked to the progression of Alzheimer's and obesity. The company aims to continue its research on eliminating other markers associated with neurodegenerative diseases. Halberd holds exclusive worldwide rights to multiple patents, enhancing its potential value for shareholders.
Halberd Corporation (OTC PINK:HALB) has filed a non-provisional patent application for a novel extracorporeal treatment targeting Covid-19 via radio frequency waves. This follows a provisional application and aims to enhance Halberd's intellectual property rights. The treatment uses a proprietary SARS-CoV-2 antibody attached to gold-coated iron nanoparticles, which, when exposed to radio frequency, neutralizes the virus. Halberd's Chairman emphasizes that while the focus remains on neurological diseases, this patent could increase scientific value.
Halberd Corporation (OTC PINK:HALB) has achieved a significant milestone by eliminating 100% of IL-6 from synthetic cerebrospinal fluid (CSF) during preliminary testing. Utilizing its patented extracorporeal and patent-pending laser eradication processes, IL-6 was eradicated in as little as three minutes. Elevated IL-6 levels are linked to neurological disorders, including PTSD, Chronic Traumatic Encephalopathy, and Alzheimer's Disease. The company plans to continue research towards eliminating other inflammatory cytokines and pursuing military endorsement for its advancements.
Halberd Corporation (OTC PINK:HALB) has filed a provisional patent application for a new process aimed at removing obesity-related proteins, cytokines, and antigens from patients' blood. This innovative approach may help alleviate severe health issues linked to obesity. The research builds on previous work in treating PTSD and Alzheimer's Disease, suggesting a potential connection between inflammatory cytokines and obesity. The treatment process is designed to be as straightforward as blood donation, with expected completion times of 30-60 minutes.
Halberd Corporation (OTC PINK:HALB) announced potential advancements in treating obesity linked to neurodegenerative diseases. Research indicates that inflammatory cytokines in the cerebrospinal fluid of neurodegenerative patients are present in individuals with obesity. Halberd's patent-pending extracorporeal treatment aims to extract these antigens, which could mitigate obesity-related health issues such as diabetes and heart disease. The company is collaborating with university partners to further this research. CEO William A. Hartman highlighted that existing medical literature informed this development.
Halberd Corporation (OTC PINK: HALB) and GTX Corp (OTC PINK: GTXO) have announced a collaboration aimed at developing treatments for Alzheimer's Disease, PTSD, and other neurological disorders. The partnership leverages both companies' technologies to enhance diagnostics and treatments for these prevalent diseases. Additionally, GTX will market Halberd's VitaShieldMaxTM Immune Support on its e-commerce platform. Halberd's Chairman highlighted the opportunity for breakthrough innovations in biomedical treatment via this strategic alliance.
Halberd Corporation (OTC PINK:HALB) has reported significant advancements in treatments for neurodegenerative diseases, including Alzheimer's, PTSD, and CTE. The company has successfully eliminated Phosphorylated Tau from cerebral spinal fluid, a key contributor to Alzheimer's-related cognitive decline. They also eliminated E.coli from buffer solutions, targeting meningitis and sepsis. Despite laboratory successes, supply shortages have caused research delays. Halberd plans to apply for an up-listing to OTCQB, contingent upon audit approval, while continuing to strengthen its intellectual property portfolio.
Halberd Corporation (OTC PINK:HALB) announced that its VitaShieldMax™ immune support product is now available on Amazon, enhancing its accessibility alongside its website. CEO William A. Hartman expressed optimism, highlighting the product's formulation based on extensive medical research. Halberd holds exclusive rights to several patented COVID-19 treatments and is compliant with OTC Market regulations. However, the company cautions investors about the uncertainties related to COVID-19, acknowledging potential impacts on operations and financial performance.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
